Results 71 to 80 of about 85,538 (123)

The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study. [PDF]

Cancers (Basel)
Ganiyani MA, Narvel H, Avudaiappan AP, Thiriveedi M, Raja Iyub MJ, Pustake M, Jatwani K, Manoharan M, Garje R.   +8 more
europepmc   +1 more source

P173 Deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: A systematic review and patient-level meta-analysis

European Urology Open Science
K.Y. Fong, E.J. Lim, K.J. Tay, H.S.S. Ho, J.S.P. Yuen, E. Aslim, K. Chen, V.H.L. Gan   +7 more
openaire   +1 more source

Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)

Annals of Oncology, 2017
Bex, A., Mulders, P., Jewett, M. A. S., Wagstaff, J., van Velthoven, R., Pes, P. M. Laguna, Wood, L., van Melick, H. H. E., Soetekouw, P., Lattouf, J. B., Powles, T., Boleti, E., de Jong, I-J., Rottey, S., Tombal, B., Marreaud, S., Collette, L., Collette, S., Blank, C. U., Haanen, J. B.   +19 more
openaire   +2 more sources

Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. [PDF]

Int J Clin Oncol
Yoshida K, Kondo T, Iizuka J, Kobari Y, Ishihara H, Fukuda H, Shimmura H, Hashimoto Y, Kobayashi H, Ishida H, Takagi T.   +10 more
europepmc   +1 more source

Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials. [PDF]

Eur Urol Open Sci
Bickley L, Fransen van de Putte EE, van den Brink L, Marandino L, van der Mijn JC, Wilgenhof S, van Thienen JV, Haanen JBAG, Boleti E, Powles T, Zondervan PJ, Graafland NM, Tippu Z, Turajlic S, Bex A.   +14 more
europepmc   +1 more source

Complete response in metastatic clear cell renal cell carcinoma following pembrolizumab-axitinib and subsequent nephrectomy: a Case Report. [PDF]

Front Immunol
Polito MG, Caruso D, Cosimati A, Ramirez Reinaga CA, Leka E, Fuschi A, Pastore AL, Carbone A, Lako K, Di Cristofano C, Petrozza V, Santini D, Spinelli GP.   +12 more
europepmc   +1 more source

Consolidative cystectomy after complete response to enfortumab vedotin plus pembrolizumab in metastatic bladder cancer: a case report. [PDF]

J Surg Case Rep
Lefranc R, Mathieu C, Ghorbel A, Léger-Vigot A, Tillou X, Waeckel T.   +5 more
europepmc   +1 more source

Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up. [PDF]

Cancers (Basel)
Ikoma H, Hamamoto S, Tasaki Y, Tomita M, Kawase K, Suzuki H, Noda Y, Usami M, Tsubouchi Y, Kato R, Sakata T, Mimura Y, Morikawa T, Nagai T, Unno R, Etani T, Naiki T, Sugiyama Y, Yasui T.   +18 more
europepmc   +1 more source

Sustained Disease Control of High-Risk Metastatic Renal Epithelioid Angiomyolipoma through Multimodal Treatment Including Repeated Thoracic Resection and Systemic Therapy: A Case Report. [PDF]

Case Rep Oncol
Omura S, Hagiuda J, Izawa N, Sasaki A, Nakagawa K, Eguchi K.   +5 more
europepmc   +1 more source

Reassessing prognosis in renal cell carcinoma with venous tumor thrombus: Prospective data from 46 cases. [PDF]

Indian J Urol
Meyyappan V, Sharma RM, Mohan A, Kavasseri LJ, Balagangatharan P, Lohith S, Reddy NB, Kharade M, Rao BV, Korrapati B.   +9 more
europepmc   +1 more source